ABBOTT LABORATORIES

Overview

Abbott Laboratories is a diversified healthcare company founded in 1900 whose principal business is the discovery, development, manufacture, and sale of a broad range of healthcare products.[1][2] Its operations are organized around four core businesses: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.[3]+3 These businesses span branded generic medicines sold mainly outside the United States, diagnostic systems and tests for laboratories and healthcare providers, pediatric and adult nutrition products, and devices for areas including diabetes care, cardiovascular care and neuromodulation.[7]+3 Representative brands and platforms include Alinity and ARCHITECT in diagnostics, Similac, Ensure and PediaSure in nutrition, and FreeStyle Libre, MitraClip and HeartMate in medical devices.[11]+3

Abbott has a broad international footprint, with 89 manufacturing facilities globally and research and development facilities in the United States, Colombia, India, Singapore, Spain and the United Kingdom.[15][16] The company generated $41.95 billion in net sales in 2024, and its sales base is geographically diverse across the United States and many international markets.[17] Abbott states that its 114,000 employees serve people in more than 160 countries.[18] Its stated mission centers on helping people live more fully through healthcare products and technologies across all stages of life.[19] [1]+18

Products & services

Abbott’s nutrition portfolio includes infant and follow-on formulas such as Similac, Similac 360 Total Care, Similac NeoSure, Similac Alimentum and EleCare; adult and pediatric nutrition brands including Ensure, Glucerna, PediaSure, Juven and Pedialyte; and enteral-feeding products such as Jevity, Osmolite, Nepro, Vital and the Freego enteral pump and sets.[12]+2 Abbott’s established pharmaceuticals include Creon for pancreatic exocrine insufficiency; Duspatal and Dicetel for irritable bowel syndrome or biliary spasm; Duphaston and Femoston in women’s health; Lipanthyl, TriCor, Omacor, Physiotens and Synthroid for dyslipidemia, hypertriglyceridemia, hypertension and hypothyroidism; Serc, Brufen and Sevedol for vertigo, pain/inflammation and severe migraines; clarithromycin sold as Klacid, Claribid and Klaricid; Influvac influenza vaccine; and biosimilars in oncology and women’s health.[22]+5

Diagnostic products include Alinity, ARCHITECT and Cell-Dyn core-lab and transfusion systems for immunoassay, clinical chemistry, hematology and transfusion serology, used in screening or diagnosis across cancer, cardiac and metabolic disorders, thyroid function, fertility, neurologic and infectious diseases including hepatitis and HIV, as well as therapeutic drug monitoring and SARS‑CoV‑2 serology.[11] Molecular diagnostics include the Alinity m and m2000 PCR systems, which automate extraction, purification and preparation of DNA and RNA from patient samples and detect HIV, hepatitis, HPV, sexually transmitted infections, SARS‑CoV‑2, influenza A & B and RSV, along with Vysis FISH genomic oncology tests.[28] Abbott also offers i-STAT and i-STAT Alinity point-of-care systems and cartridges for blood gas, chemistry, electrolytes, coagulation and immunoassay testing; BinaxNOW and Panbio rapid tests; the m-PIMA HIV-1/2 Viral Load Test; the ID NOW rapid molecular system; Afinion and Cholestech LDX cardiometabolic tests; a toxicology business; and lab automation and informatics products including GLP systems Track, RALS and the AlinIQ suite of tools and professional services.[29]+2

Medical devices include Assurity MRI and Endurity MRI pacemakers; Aveir single-chamber and dual-chamber leadless pacemakers; Ellipse, Fortify Assura and Gallant implantable cardioverter defibrillators; Quadra Assura MP with cardiac resynchronization therapy and MultiPoint Pacing; and Confirm Rx, Jot Dx and ASSERT-IQ implantable cardiac monitors.[32] Abbott’s electrophysiology portfolio includes TactiFlex, TactiCath and FlexAbility ablation catheters, EnSite cardiac mapping systems, Agilis NxT and Swartz introducer catheters, the Advisor HD Grid mapping catheter and ViewFlex intracardiac echocardiography catheters.[33] Other device families include HeartMate left ventricular assist devices, the CardioMEMS HF System pulmonary artery sensor, the CentriMag acute mechanical circulatory support system and patient self-testing products and services; XIENCE drug-eluting stents, vessel closure devices, TREK balloon dilatation products, PressureWire fractional flow reserve systems, Diamondback 360 atherectomy systems and the Esprit BTK resorbable scaffold; structural-heart products including MitraClip, TriClip, Portico, Navitor, Amplatzer and Tendyne; FreeStyle Libre and Lingo continuous glucose monitoring systems with sensors and data-management software; and neuromodulation systems including Proclaim Plus, Proclaim XR and Eterna spinal cord stimulators with BurstDR stimulation, Proclaim DRG, and Infinity and Liberta RC deep brain stimulation systems with directional lead technology.[34]+4

In 2024, medical devices represented 45.3% of Abbott’s net sales, diagnostics 22.3%, nutrition 20.1%, and established pharmaceuticals 12.4%.[37] [12]+21

Geographic presence

Abbott’s sales mix is majority international. In 2024, 61.1% of consolidated net sales came from outside the U.S. ($25.6 billion) and 38.9% from the U.S. ($16.3 billion). By country of sale, the U.S. was the largest market, followed by Germany ($2.5 billion, 6.1% of sales), China ($2.1 billion, 5.0%), India ($1.8 billion, 4.3%), Switzerland ($1.7 billion, 4.2%), Japan ($1.4 billion, 3.4%), and the Netherlands ($1.1 billion, 2.7%); all other countries accounted for 35.4% of sales. Abbott notes that these country figures are based on the country that sold the product.[17][38]

The company’s operating footprint is also global. Abbott’s principal corporate offices are in Abbott Park, Illinois, and it owned or leased about 44 million square feet of property at year-end 2024. It operated 89 manufacturing facilities worldwide, including 32 for Medical Devices, 21 for Diagnostic Products, 23 for Established Pharmaceutical Products, and 13 for Nutritional Products. Its workforce is similarly international: Abbott employed about 114,000 people at year-end 2024, with 69% located outside the U.S.[39]+4

Geographic exposure varies by segment. Established Pharmaceutical Products are manufactured worldwide but marketed and sold outside the United States in emerging markets, and the segment recorded no U.S. sales in 2024 versus $5.2 billion internationally. Abbott’s other major businesses also skew international: Nutrition generated $4.7 billion internationally versus $3.7 billion in the U.S., Diagnostics $5.5 billion versus $3.8 billion, and Medical Devices $10.2 billion versus $8.8 billion.[7][37] [17]+8

Business segments

Abbott Laboratories officially reports four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices, based on the internal management reporting used by its chief operating decision maker.[44][45]

By 2024 reportable-segment net sales, Medical Devices was the largest segment at about 45% of segment revenue; this segment includes rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products sold worldwide.[46][47] Diagnostic Products contributed about 22% and covers diagnostic systems and tests worldwide, with Abbott noting the aggregation of core laboratory diagnostics, rapid diagnostics, molecular diagnostics, and point-of-care diagnostics within this segment.[48][47] Nutritional Products contributed about 20% and consists of worldwide adult and pediatric nutritional products.[49][47] Established Pharmaceutical Products contributed about 12% and consists of a broad line of branded generic pharmaceuticals sold internationally, primarily outside the U.S. in emerging markets.[50]+2 Abbott also reported a very small "Other" category of roughly 0.04% of 2024 net sales.[47] [44]+7

Company history

Abbott traces its origins to 1888, when Dr. Wallace C. Abbott began producing scientifically formulated medicines, and the company was incorporated in Illinois in 1900.[51][1] Over the following decades, Abbott expanded from its original pharmaceutical base into broader healthcare fields; a notable step came in diagnostics in 1972, when it introduced the ABA-100 blood chemistry analyzer and its first hepatitis test, followed by additional hepatitis-screening products in 1974.[52] In 1985, Abbott launched the first FDA-approved HIV test, an important milestone in its diagnostics business.[52][53]

Abbott later reshaped its portfolio through major separations and acquisitions. It completed the spin-off of Hospira in 2004 and separated its research-based pharmaceuticals business into AbbVie effective January 1, 2013.[54][55] In 2017, Abbott expanded further through the acquisitions of St. Jude Medical, which strengthened its medical devices operations, and Alere, which broadened its diagnostics presence.[56][57] [1]+7

Sources

• ABBOTT LABORATORIES — Full financial report (2024 Y)
  48 citations

  [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50]
• www.abbott.com[18]
• www.abbott.com[19]
• www.abbott.com[51]
• www.corelaboratory.abbott[52]
• www.corelaboratory.abbott[53]
• www.abbottinvestor.com[54]
• www.abbott.com[55]
• abbott.mediaroom.com[56]
• abbott.mediaroom.com[57]